GSK Aktie 119642297 / GB00BN7SWP63
20.14
EUR
0.39
EUR
1.97 %
30.10.2025
BMN
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
GSK Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | GSK PLC Registered Shs | 4.53 | 0.61 | GBP |
| 2023 | GSK PLC Registered Shs | 4.00 | 0.58 | GBP |
| 2022 | GSK PLC Registered Shs | 4.26 | 0.61 | GBP |
| 2021 | GSK PLC Registered Shs | 4.98 | 1.00 | GBP |
| 2020 | GSK PLC Registered Shs | 5.96 | 1.00 | GBP |
| 2019 | GSK PLC Registered Shs | 4.50 | 1.00 | GBP |
| 2018 | GSK PLC Registered Shs | 5.36 | 1.00 | GBP |
| 2017 | GSK PLC Registered Shs | 6.05 | 1.00 | GBP |
| 2016 | GSK PLC Registered Shs | 5.12 | 1.00 | GBP |
| 2015 | GSK PLC Registered Shs | 5.83 | 1.00 | GBP |
Gewinn je Aktie- GSK
| 0.6 24 | 1.2 23 | 3.7 22 | 1.1 21 | 1.4 20 | 1.2 19 | 0.9 18 |
Umsatz je Aktie- GSK
| 7.6 24 | 7.4 23 | 7.2 22 | 8.4 21 | 8.5 20 | 8.4 19 | 7.8 18 |
KGV- GSK
| 21.3 24 | 11.9 23 | 3.9 22 | 18.3 21 | 11.6 20 | 18.9 19 | 20.2 18 |
GSK PLC Registered Shs: Die Aktie (in GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 0.63 | 1.22 | 3.71 | 1.10 | 1.44 | 1.17 | 0.92 |
| Gewinn je Aktie (unverwässert) | 0.63 | 1.22 | 3.71 | 1.10 | 1.44 | 1.17 | 0.92 |
| Gewinn je Aktie (verwässert) | 0.62 | 1.20 | 3.66 | 1.08 | 1.43 | 1.16 | 0.91 |
| Dividende je Aktie | 0.61 | 0.58 | 0.61 | 1.00 | 1.00 | 1.00 | 1.00 |
| Veränderung Dividende je Aktie in % | 5.17 | -5.31 | -38.75 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 2’444.00 | 2’247.00 | 3’467.00 | 3’999.00 | 3’977.00 | 3’953.00 | 3’927.00 |
GSK PLC Registered Shs: Unternehmenskennzahlen (in GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 7.58 | 7.38 | 7.18 | 8.42 | 8.46 | 8.41 | 7.75 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 21.32 | 11.92 | 3.87 | 18.33 | 11.62 | 18.95 | 20.23 |
| KGV (Jahresendkurs, Gewinn verwässert) | 21.66 | 12.10 | 3.93 | 18.56 | 11.76 | 19.21 | 20.46 |
| Dividendenrendite Jahresende in % | 4.53 | 4.00 | 4.26 | 4.98 | 5.96 | 4.50 | 5.36 |
| Eigenkapitalquote in % | 22.01 | 21.68 | 16.79 | 26.98 | 25.87 | 23.03 | 6.32 |
| Fremdkapitalquote in % | 77.99 | 78.32 | 83.21 | 73.02 | 74.13 | 76.97 | 93.68 |
GSK PLC Registered Shs: GuV (in Mio. GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 31’376.00 | 30’328.00 | 29’324.00 | 34’114.00 | 34’099.00 | 33’754.00 | 30’821.00 |
| Umsatzveränderung in % | 3.46 | 3.42 | -14.04 | 0.04 | 1.02 | 9.52 | 2.10 |
| Bruttoergebnis vom Umsatz | 21’900.00 | 21’252.00 | 19’462.00 | 22’304.00 | 23’123.00 | 22’885.00 | 20’925.00 |
| Bruttoergebnisveränderung in % | 3.05 | 9.20 | -12.74 | -3.54 | 1.04 | 9.37 | 4.18 |
| Operatives Ergebnis | 5’662.00 | 6’993.00 | 6’682.00 | 7’400.00 | 8’183.00 | 7’783.00 | 7’999.00 |
| Veränderung Operatives Ergebnis in % | -19.03 | 4.65 | -9.70 | -9.57 | 5.14 | -2.70 | 0.31 |
| Ergebnis vor Steuern | 3’480.00 | 6’069.00 | 5’630.00 | 5’409.00 | 6’935.00 | 6’147.00 | 4’769.00 |
| Veränderung Ergebnis vor Steuern in % | -42.66 | 7.80 | 4.09 | -22.00 | 12.82 | 28.89 | 35.79 |
| Ergebnis nach Steuer | 2’575.00 | 4’928.00 | 4’461.00 | 4’385.00 | 5’749.00 | 4’645.00 | 3’623.00 |
| Veränderung Ergebnis nach Steuer in % | -47.75 | 10.47 | 1.73 | -23.73 | 23.77 | 28.21 | 136.49 |
GSK PLC Registered Shs: Bilanz (in Mio. GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 46’377 | 46’210 | 50’050 | 57’761 | 59’623 | 61’335 | 54’394 |
| Langzeit Gesamtverbindlichk. je Aktie | 6.05 | 6.20 | 6.75 | 8.51 | 9.40 | 9.41 | 8.10 |
| Eigenkapital | 13’086 | 12’795 | 10’096 | 21’342 | 20’808 | 18’357 | 3’672 |
| Veränderung Eigenkapital in % | 2.43 | 25.94 | -29.60 | 3.21 | 27.90 | 161.58 | - |
| Bilanzsumme | 59’463 | 59’005 | 60’146 | 79’103 | 80’431 | 79’692 | 58’066 |
| Veränderung Bilanzsumme in % | 0.78 | -1.90 | -23.96 | -1.65 | 0.93 | 37.24 | 2.99 |
GSK PLC Registered Shs: Sonstige Angaben (in GBP)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 0.63 | 1.22 | 3.71 | 1.10 | 1.44 | 1.17 | 0.92 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -48.07 | -67.26 | 239.07 | -24.14 | 23.05 | 27.35 | 134.80 |
| Gewinn je Aktie (verwässert) | 0.62 | 1.20 | 3.66 | 1.08 | 1.43 | 1.16 | 0.91 |
| Veränderung Gewinn je Aktie (verwässert) in % | -48.14 | -67.27 | 238.39 | -24.13 | 23.22 | 27.07 | 135.10 |
| Anzahl Mitarbeiter | 68’629 | 70’212 | 69’400 | 90’096 | 94’066 | 99’437 | 95’490 |
| Veränderung Anzahl Mitarbeiter in % | -2.25 | 1.17 | -22.97 | -4.22 | -5.40 | 4.13 | -3.02 |
GSK PLC Registered Shs Termine
| Unternehmen | Event | Datum |
|---|---|---|
| GSK PLC Registered Shs | Quartalszahlen | 04.02.2026 |
| GSK PLC Registered Shs | Quartalszahlen | 06.05.2026 |
| GSK PLC Registered Shs | Quartalszahlen | 05.08.2026 |
| GSK PLC Registered Shs | Quartalszahlen | 04.11.2026 |
| GSK PLC Registered Shs | Quartalszahlen | 10.02.2027 |
GSK PLC Registered Shs vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2025 Earnings Release | 29.10.2025 |
| Quartalszahlen | Q2 2025 Earnings Release | 30.07.2025 |
| Hauptversammlung | Annual General Meeting | 07.05.2025 |
| Quartalszahlen | Q1 2025 Earnings Release | 30.04.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 05.02.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 30.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 31.07.2024 |
| Hauptversammlung | Annual General Meeting | 08.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 01.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 31.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 01.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 26.07.2023 |
| Hauptversammlung | Annual General Meeting | 03.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 26.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 01.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 02.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.07.2022 |
| Hauptversammlung | Annual General Meeting | 04.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 27.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 09.02.2022 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 95’490 | 99’437 | 94’066 | 90’096 | 69’400 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.32 | 0.34 | 0.36 | 0.38 | 0.42 |
Bilanz (in Mio. GBP) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 16’927 | 19’491 | 20’247 | 18’674 | 20’769 |
| Summe Anlagevermögen | 41’139 | 60’201 | 60’184 | 60’429 | 39’377 |
| Summe Aktiva | 58’066 | 79’692 | 80’431 | 79’103 | 60’146 |
Bilanz (in Mio. GBP) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 54’394 | 61’335 | 59’623 | 57’761 | 50’050 |
| Summe Eigenkapital | 3’672 | 18’357 | 20’808 | 21’342 | 10’096 |
| Summe Passiva | 58’066 | 79’692 | 80’431 | 79’103 | 60’146 |
Adresse
| 79 New Oxford Street, WC1A 1DG London | |
| Telefon | +44 (20) 8047-5000 |
| URL | http://www.gsk.com |
Management
|
Anita Kidgell
Senior Vice President-Corporate Strategy |
|
Anne C. Beal
Independent Non-Executive Director |
|
Anne-Marie Martin
Senior VP & Global Head-Experimental Medicine Unit |
|
Charles A. Bancroft
Senior Independent Non-Executive Director |
|
Claire Lund
Head-Environmental Sustainability |
|
David Simon Redfern
President-Corporate Development |
|
Diana Conrad
Chief People Officer |
|
Elizabeth McKee Anderson
Independent Non-Executive Director |
|
Emma N. Walmsley
Chief Executive Officer & Executive Director |
|
Frannie DeFranco
Director-Philadelphia Investor Relations |
|
Gavin Screaton
Independent Non-Executive Director |
|
Graham Rivers
Vice President & Financial Controller |
|
Hal V. Barron
Non-Independent Non-Executive Director |
|
Harry C. Dietz
Independent Non-Executive Director |
|
James Ford
Group General Counsel, Head-Legal & Compliance |
|
Jeannie T. Lee
Non-Executive Director |
|
Jonathan Richard Symonds
Non-Executive Chairman |
|
Julie Brown
Chief Financial Officer & Executive Director |
|
Luke Miels
Chief Executive Officer-Designate |
|
María Cristina de Luna Basagoiti
General Manager-Spain |
|
Maya Martinez-Davis
President-US Pharmaceuticals |
|
Michael Elmore
Senior Vice President |
|
Mick John Readey
Investor Relations Contact |
|
Philip Thomson
President-Global Affairs |
|
Regis Jean-Pierre Simard
President-Global Supply Chain |
|
Shobie Ramakrishnan
Chief Digital & Technology Officer |
|
Timothy Woodthorpe
Group Treasurer & Senior Vice President |
|
Tony Wood
Chief Scientific Officer |
|
Victoria A. Whyte
Secretary |
|
Vishal Sikka
Independent Non-Executive Director |
|
Wendy Becker
Independent Non-Executive Director |